Your browser is no longer supported

For the best possible experience using our website we recommend you upgrade to a newer version or another browser.

Your browser appears to have cookies disabled. For the best experience of this website, please enable cookies in your browser

We'll assume we have your consent to use cookies, for example so you won't need to log in each time you visit our site.
Learn more

NICE rejects tumour drug

  • 1 Comment

NICE has rejected imatinib (Glivec) as an adjuvant treatment for people who have had a gastrointestinal stromal tumour removed and who are at risk of the cancer recurring.

NICE said there was not currently enough evidence about the clinical effectiveness of imatinib, such as whether it extends life expectancy, to recommend it for the NHS.

Introducing Nursing Times Learning

Online training units, written and reviewed by experts. Earn two hours’ CPD and a personalised certificate for your portfolio.

Subscribers get five FREE learning units and non-subscribers can access each learning unit for £10 + VAT.

Click on the topics below to get started:

  • 1 Comment

Readers' comments (1)

  • Please explain why they have not consulted with patients and relatives in htis decision. We as a family were told terminal and end stage approaching but thankfully glivec prescribed. We got another 3.5 years post script. My family member got her life back also for a short time before she died....there is no research that will ever be able to quantify the the 'quality' regardless of methodology. Health professional observation.

    Unsuitable or offensive? Report this comment

Have your say

You must sign in to make a comment

Please remember that the submission of any material is governed by our Terms and Conditions and by submitting material you confirm your agreement to these Terms and Conditions. Links may be included in your comments but HTML is not permitted.